The Cooper Companies, Inc. (NASDAQ:COO) Given Average Recommendation of “Moderate Buy” by Brokerages

The Cooper Companies, Inc. (NASDAQ:COO) has been given an average rating of “Moderate Buy” by the ten brokerages that are covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $110.25.

COO has been the subject of a number of recent analyst reports. Piper Sandler reaffirmed an “overweight” rating and issued a $115.00 price objective (down previously from $120.00) on shares of Cooper Companies in a research note on Friday, March 7th. Citigroup reduced their target price on Cooper Companies from $115.00 to $110.00 and set a “buy” rating for the company in a report on Friday, March 7th. StockNews.com downgraded Cooper Companies from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Wells Fargo & Company boosted their price objective on Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research report on Friday, December 6th. Finally, Morgan Stanley decreased their target price on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a research note on Friday, December 6th.

Cooper Companies Stock Performance

Shares of COO stock opened at $84.07 on Tuesday. Cooper Companies has a 52 week low of $77.05 and a 52 week high of $112.38. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. The business has a 50 day moving average of $89.90 and a two-hundred day moving average of $97.88. The company has a market cap of $16.81 billion, a P/E ratio of 43.11, a PEG ratio of 2.25 and a beta of 1.02.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.92. The business had revenue of $964.70 million for the quarter, compared to analysts’ expectations of $981.25 million. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. As a group, analysts anticipate that Cooper Companies will post 3.98 EPS for the current year.

Hedge Funds Weigh In On Cooper Companies

Several large investors have recently added to or reduced their stakes in COO. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of Cooper Companies during the fourth quarter valued at approximately $691,000. Highland Capital Management LLC acquired a new stake in Cooper Companies during the fourth quarter worth $4,004,000. Caprock Group LLC bought a new stake in Cooper Companies in the 4th quarter valued at $282,000. Franklin Resources Inc. raised its stake in shares of Cooper Companies by 194.0% in the 3rd quarter. Franklin Resources Inc. now owns 48,892 shares of the medical device company’s stock valued at $5,265,000 after buying an additional 32,260 shares in the last quarter. Finally, Principal Financial Group Inc. raised its stake in shares of Cooper Companies by 6.6% in the 3rd quarter. Principal Financial Group Inc. now owns 238,305 shares of the medical device company’s stock valued at $26,295,000 after buying an additional 14,687 shares in the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.